FRIDAY, July 15, 2022 — People shouldn’t take the drugs colchicine and fluvoxamine to treat mild to moderate COVID-19, the World Health Organization (WHO) is warning.
The antidepressant drug fluvoxamine (Luvox) and the gout drug colchicine are commonly used and inexpensive drugs that have received considerable interest as potential COVID-19 treatments.
However, there is insufficient evidence that either drug improves important outcomes for patients, according to a WHO report produced by a panel of experts and recently published online in The BMJ.
Fluvoxamine should only be used in clinical trials, the WHO report advised, based on data from three randomized controlled trials involving more than 2,000 patients.
The organization strongly advised against using colchicine at all, based on data from seven clinical trials involving nearly 16,500 patients.
After reviewing the evidence, the WHO panel concluded that almost all well-informed patients should choose not to take either drug for COVID-19.
Previously, the WHO has strongly recommended the use of nirmatrelvir and ritonavir in treating COVID-19. It has also issued conditional recommendations for sotrovimab, remdesivir and molnupiravir for high-risk patients with non-severe COVID.
For patients with severe COVID-19, the WHO strongly recommends corticosteroids, with the addition of IL-6 receptor blockers or baricitinib, the panel said in a journal news release.
But it advises against the use of convalescent plasma, ivermectin and hydroxychloroquine in COVID patients, no matter how severe their disease.
Sources
- The BMJ, news release, July 13, 2022
© 2022 HealthDay. All rights reserved.
Posted July 2022
